| Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer A Calles, X Liao, LM Sholl, SJ Rodig, GJ Freeman, M Butaney, C Lydon, ... Journal of Thoracic Oncology 10 (12), 1726-1735, 2015 | 279 | 2015 |
| Carlumab, an anti-CC chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label … I Brana, A Calles, PM LoRusso, LK Yee, TA Puchalski, S Seetharam, ... Targeted oncology 10, 111-123, 2015 | 228 | 2015 |
| A functional landscape of resistance to ALK inhibition in lung cancer FH Wilson, CM Johannessen, F Piccioni, P Tamayo, JW Kim, ... Cancer cell 27 (3), 397-408, 2015 | 197 | 2015 |
| Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment E Garralda, K Paz, PP López-Casas, S Jones, A Katz, LM Kann, ... Clinical Cancer Research 20 (9), 2476-2484, 2014 | 183 | 2014 |
| Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor–associated myocarditis P Thavendiranathan, L Zhang, A Zafar, ZD Drobni, SS Mahmood, ... Journal of the American College of Cardiology 77 (12), 1503-1516, 2021 | 148 | 2021 |
| Colon cancer molecular subtypes identified by expression profiling and associatedto stroma, mucinous type and different clinical behavior B Perez Villamil, A Romera Lopez, S Hernandez Prieto, G Lopez Campos, ... BMC cancer 12, 1-13, 2012 | 148 | 2012 |
| Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors T Kosaka, J Tanizaki, RM Paranal, H Endoh, C Lydon, M Capelletti, ... Cancer research 77 (10), 2712-2721, 2017 | 141 | 2017 |
| The role of immunotherapy in small cell lung cancer A Calles, G Aguado, C Sandoval, R Álvarez Clinical and Translational Oncology 21, 961-976, 2019 | 121 | 2019 |
| Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study GJ Hanna, NL Busaidy, NG Chau, LJ Wirth, JA Barletta, A Calles, ... Clinical Cancer Research 24 (7), 1546-1553, 2018 | 120 | 2018 |
| Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma A Calles, LM Sholl, SJ Rodig, AK Pelton, JL Hornick, M Butaney, C Lydon, ... Clinical Cancer Research 21 (12), 2851-2860, 2015 | 115 | 2015 |
| Checkpoint blockade in lung cancer with driver mutation: choose the road wisely. A Calles, JW Riess, JR Brahmer American Society of Clinical Oncology Educational book. American Society of …, 2020 | 100 | 2020 |
| Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft MP Morelli, E Calvo, E Ordoñez, MJ Wick, BR Viqueira, PP Lopez-Casas, ... Journal of Clinical Oncology 30 (4), e45-e48, 2012 | 95 | 2012 |
| Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline-and taxane-refractory breast cancer JA Garcia-Saenz, M Martin, A Calles, C Bueno, L Rodriguez, J Bobokova, ... Journal of chemotherapy 20 (5), 632-639, 2008 | 80 | 2008 |
| Intratumoral nanoplexed poly I: C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors I Márquez-Rodas, F Longo, ME Rodriguez-Ruiz, A Calles, S Ponce, ... Science Translational Medicine 12 (565), eabb0391, 2020 | 76 | 2020 |
| Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer AB Custodio, JL González-Larriba, J Bobokova, A Calles, R Alvarez, ... Journal of thoracic oncology 4 (7), 891-910, 2009 | 76 | 2009 |
| UNcommon EGFR mutations: international case series on efficacy of osimertinib in real-life practice in first-LiNe setting (UNICORN) J Bar, N Peled, S Schokrpur, M Wolner, O Rotem, N Girard, FA Nana, ... Journal of thoracic oncology 18 (2), 169-180, 2023 | 73* | 2023 |
| Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer E Calvo, VJ Chen, M Marshall, U Ohnmacht, SM Hynes, E Kumm, ... Investigational new drugs 32, 955-968, 2014 | 69 | 2014 |
| Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines A Calles, N Kwiatkowski, BK Cammarata, D Ercan, NS Gray, PA Jänne Molecular oncology 9 (1), 260-269, 2015 | 61 | 2015 |
| Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring B Gyawali, EGE De Vries, U Dafni, T Amaral, J Barriuso, J Bogaerts, ... ESMO open 6 (3), 100117, 2021 | 60 | 2021 |
| Safety and pharmacokinetics/pharmacodynamics of the first-in-class dual action HER3/EGFR antibody MEHD7945A in locally advanced or metastatic epithelial tumors D Juric, R Dienstmann, A Cervantes, M Hidalgo, W Messersmith, ... Clinical Cancer Research 21 (11), 2462-2470, 2015 | 60 | 2015 |
